Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Sec...
July 22 2019 - 4:01PM
Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare
company focused on developing and commercializing innovative
therapies for women’s health and prostate cancer, today announced
it will hold a webcast and conference call beginning at 8:30
a.m. Eastern Time / 5:30 a.m. Pacific
Time on Tuesday, July 23, 2019, to discuss results from
the Phase 3 LIBERTY 2 study of once-daily relugolix combination
therapy in women with uterine fibroids and heavy menstrual
bleeding. The company will also discuss results from a separate
bioequivalence study comparing single-tablet relugolix combination
therapy with the two-tablet regimen used in the LIBERTY clinical
program.
Webcast/Teleconference Details To participate
in the live conference call, please dial 1-800-532-3746 for
domestic callers and 1- 470-495-9166 for international
callers. A live webcast of the conference call will also be
available on the investor relations page of Myovant’s website at
investors.myovant.com. After the live webcast, the event will
remain archived on Myovant’s website for at least 30 days.
About Myovant Sciences Myovant
Sciences aspires to be the leading healthcare company focused
on innovative treatments for women's health and prostate cancer.
Myovant's lead product candidate is relugolix, an oral once-daily
small molecule that acts as a GnRH receptor antagonist. Myovant has
three late-stage clinical programs for relugolix ongoing in uterine
fibroids, endometriosis and prostate cancer. Myovant is also
developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist,
that has completed a Phase 2a study for the treatment of female
infertility as part of assisted reproduction. Takeda
Pharmaceuticals International AG granted Myovant an exclusive,
worldwide license to develop and commercialize relugolix
(excluding Japan and certain other Asian countries) and
an exclusive license to develop and commercialize MVT-602 in all
countries worldwide. Over time, Myovant intends to expand its
development pipeline to include other potential treatments for
women's health and prostate cancer. For more information, please
visit Myovant's website at www.myovant.com. Follow @Myovant on
Twitter and LinkedIn
(https://www.linkedin.com/company/myovant-sciences).
Investor Contact: Frank Karbe Chief Financial
Officer Myovant Sciences, Inc. investors@myovant.com
Media Contact: Sheryl Seapy Pure Communications
sseapy@purecommunications.com 949.903.4750
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2024 to May 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From May 2023 to May 2024